<DOC>
	<DOC>NCT00051532</DOC>
	<brief_summary>The purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma [HCC]).</brief_summary>
	<brief_title>Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Seocalcitol</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Hospital in or outpatients Either sex Aged 1875 years With hepatocellular carcinoma, verified by histology/cytology, which is not amenable to curative treatment or transplantation. Patients must have measurable disease, and be classifiable as to Barcelona Clinic Liver Cancer (BCLC) stage 0, as described in Llovet JM et al. Hepatology 1999;29:6267. Patients treated with chemotherapy or other anticancer therapy within 4 weeks before visit 1 Patients with another primary tumor, except for basocellular carcinoma of the skin or in situ carcinoma of the cervix, within the last 2 years A history of renal stone(s) A life expectancy of &lt; 3 months World Health Organization (WHO) performance status 3 or 4 Okuda stage III. Patients with hypercalcemia, or other clinically important laboratory abnormalities Patients with previous/current calcium metabolic disease, taking calciumlowering therapy, or medication known to affect systemic calcium metabolism are also excluded. All patients must give their signed informed consent to join the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>hepatocellular</keyword>
	<keyword>carcinoma</keyword>
	<keyword>liver</keyword>
	<keyword>cancer</keyword>
</DOC>